为转录因子Brachyury开发一个小分子下调器的开发
Davis H Chase1, Adrian M Bebenek2, Pengju Nie2
1Department of Chemistry, Yale University, New Haven, CT-06511.
Angewandte Chemie (International ed. in English)
|February 13, 2024
概括
科学家们开发了DHC-156,一种新型的小分子,针对"不可抗药"的brachyury瘤基因. 这种化合物有效地降低了brachyury水平,为瘤治疗提供了一个有前途的新疗法策略.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药物发现 药物发现 药物发现
背景情况:
- 勃拉基尤里是一种致癌的转录因子,驱动着胆瘤的生长.
- 向brachyury在治疗上是有前途的,但由于其作为转录因子的性质而具有挑战性.
- 之前的研究集中在上游激酶上,阿法替尼 (afatinib) 显示出调节brachyury的潜力.
研究的目的:
- 开发一种新型的小分子抑制剂,直接向和降低brachyury.
- 探索一种基于结构的药物设计方法,用于创建强大的brachyury调节器.
- 为了证明直接brachyury调制的可行性为chordoma治疗.
主要方法:
- 使用基于结构的药物设计方法.
- 采用质谱学和X射线晶体学用于化合物开发.
- 设计的DHC-156可以选择性地结合brachyury,消除激酶抑制.
主要成果:
- 开发了DHC-156,一种小分子,可以强烈降低brachyury.
- 在不抑制激酶的情况下,DHC-156可选择性地结合brachyury.
- 通过转化后的brachyury下调证明了无可逆转的chordoma瘤细胞生长的损害.
结论:
- 直接调节brachyury是可行的和治疗上可行的.
- DHC-156代表了开发强效基向疗法的新支架.
- 这种方法为治疗诸如冠状腺瘤之类的肌肉驱动癌症开辟了新的途径.
相关概念视频
Master Transcription Regulators
6.9K
Master transcription regulators are regulatory proteins that are predominantly responsible for regulating the expression of multiple genes. Often these genes work in concert to drive a complex process. Activation of a master transcription regulator can lead to a cascade of transcriptional activation necessary for that outcome. These regulators can directly bind to the regulatory sequences of the various genes involved, or they can indirectly regulate transcription by binding to regulatory...
6.9K
RNA Polymerase II Accessory Proteins
9.2K
Proteins that regulate transcription can do so either via direct contact with RNA Polymerase or through indirect interactions facilitated by adaptors, mediators, histone-modifying proteins, and nucleosome remodelers. Direct interactions to activate transcription is seen in bacteria as well as in some eukaryotic genes. In these cases, upstream activation sequences are adjacent to the promoters, and the activator proteins interact directly with the transcriptional machinery. For example, in...
9.2K
Co-activators and Co-repressors
7.4K
Gene transcription is regulated by the synergistic action of several proteins that form a complex at a gene regulatory site. This is observed in eukaryotes, where the regulation of gene expression is a complex process. Regulatory proteins in eukaryotes can broadly be classified into two types – regulators that bind directly to specific DNA sequences and co-regulators that associate with regulatory proteins but cannot directly bind to the DNA. These co-regulators are further divided into...
7.4K
Combinatorial Gene Control
8.3K
Combinatorial gene control is the synergistic action of several transcriptional factors to regulate the expression of a single gene. The absence of one or more of these factors may lead to a significant difference in the level of gene expression or repression.
The expression of more than 30,000 genes is controlled by approximately 2000-3000 transcription factors. This is possible because a single transcription factor can recognize more than one regulatory sequence. The specificity in gene...
The expression of more than 30,000 genes is controlled by approximately 2000-3000 transcription factors. This is possible because a single transcription factor can recognize more than one regulatory sequence. The specificity in gene...
8.3K
Transcription Factors
75.8K
Tissue-specific transcription factors contribute to diverse cellular functions in mammals. For example, the gene for beta globin, a major component of hemoglobin, is present in all cells of the body. However, it is only expressed in red blood cells because the transcription factors that can bind to the promoter sequences of the beta globin gene are only expressed in these cells. Tissue-specific transcription factors also ensure that mutations in these factors may impair only the function of...
75.8K
TGF - β Signaling Pathway
7.4K
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
7.4K


